Effects of amlodipine and isosorbide dinitrate on exercise-induced and ambulatory ischemia in patients with chronic stable angina pectoris

Cardiovascular Drugs and Therapy

Volumn 11, Issue 5, 1997, Pages 629-635

  Steffensen, Rolf ^a   Melchior, Thomas ^b   Bech, Jan ^c   Nissen, Henrik ^d   Haastrup, Benedikte ^d   Grande, Peer ^a   Rasmussen, Verner ^b   Hansen, Jørgen Fischer ^b   Skagen, Knud ^c   Haghfelt, Torben ^d  

^a Rigshospitalet   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Ambulatory ECG monitoring; Amlodipine; Angina pectoris; Exercise testing; Isosorbide dinitrate

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; CORONARY VASODILATING AGENT; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE;

ADULT; AGED; AMBULATORY MONITORING; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DYSPNEA; EDEMA; ELECTROCARDIOGRAPHY MONITORING; EXERCISE TEST; FATIGUE; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT DEPRESSION; SUSTAINED RELEASE PREPARATION; TIME; TINNITUS; VERTIGO;

ADULT; AGED; AMLODIPINE; ANGINA PECTORIS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY, AMBULATORY; EXERCISE TEST; FEMALE; HEART RATE; HUMANS; ISOSORBIDE DINITRATE; MALE; MIDDLE AGED; VASODILATOR AGENTS;

EID: 6844236360     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007726722284     Document Type: Article

References (36)

1. Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995;50:560-586.
2. Williams DM, Cubeddu LX. Amlodipine pharmacokinetics in healthy volunteers. J Clin Pharmacol 1988;28:990-994.
3. Mroczek WJ, Burris JF, Allenby KS. A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure in hypertensive patients. J Cardiovasc Pharmacol 1988;12 (Suppl. 7):S79-S84.
4. Faulkner JK, McGibney D, Chasseaud LF, Perry JL, Taylor IW. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br J Clin Pharmacol 1986;22:21-25.
5. Burges RA, Dodd MG. Amlodipine. Cardiovasc Drug Review 1990;8:25-44.
6. Kinnard DR, Harris M, Hossack KF. Endurance testing for evaluation of antianginal therapy with amlodipine, a calcium channel blocking agent. J Am Coll Cardiol 1988;12:791-796.
7. Glasser SP, West TW. Clinical safety and efficacy of once-a-day amlodipine for chronic stable angina pectoris. Am J Cardiol 1988;62:518-522.
8. Taylor SH, Lee P, Jackson N, Cocco G. A four-week double-blind, placebo-controlled, parallel dose-response study of amlodipine in patients with stable exertional angina pectoris. Am Heart J 1989;118:1133-1134.
9. Chahine RA, Feldman RL, Giles TD, Nicod P, Raizner AE, Weiss RJ, Vanov SK. Randomized placebo-controlled trial of amlodipine in vasospastic angina. Amlodipine Study 160 Group. J Am Coll Cardiol 1993;21:1365-1370.
10. Deanfield JE, Detry JM, Lichtlen PR, Magnani B, Sellier P, Thaulow E. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: Double-blind Circadian Anti-Ischemia Program in Europe (CAPE Trial). J Am Coll Cardiol 1994;24:1460-1467.
11. Heber ME, Brigden G, Al-Khawaja I, Raftery EB. 24 h blood pressure control with the once daily calcium antagonist, amlodipine. Br J Clin Pharmacol 1989;27:359-365.
12. Frick MH, McGibney D, Tyler HM. A dose-response study of amlodipine in mild to moderate hypertension. J Intern Med 1989;225:101-105.
13. Lund-Johansen P, Omvik P, White W, Digranes O, Heiland B, Jordal O, Stray T. Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertension. J Hypertens 1990;8:1129-1136.
14. Silke B, Goldhammer E, Sharma SK, Verma SP, Taylor SH. An exercise hemodynamic comparison of verapamil, diltiazem, and amlodipine in coronary artery disease. Cardiovasc Drugs Ther 1990;4:457-464.
15. Bernink PJLM, de Weerd P, ten Cate FJ, et al. and Coinvestigators. An 8-week double-blind study of amlodipine and diltiazem in patients with stable exertional angina pectoris. J Cardiovasc Pharmacol 1991;17(Supp. 1):S53-S56.
16. Singh S, Doherty J, Udhoji V, et al. Amlodipine versus nadolol in patients with stable angina pectoris. Am Heart J 1989;118:1137-1138.
17. Davies RF, Habibi H, Klinke WP, et al. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators. J Am Coll Cardiol 1995;25:619-625.
18. Jespersen CM, Rasmussen V. Value of a bipolar modified inferior lead in detection of inferior myocardial ischaemia. Br Heart J 1988;60:287-289.
19. Kailasam MT, Parmer RJ, Cervenka JH, et al. Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. Hypertension 1995;26:143-149.
20. Cappuccio FP, Markandu ND, Sagnella GA, Singer DR, Buckley MG, Miller MA, MacGrego GA. Effects of amlodipine on urinary sodium excretion, renin-angiotensin-aldosterone system, atrial natriuretic peptide and blood pressure in essential hypertension. J Hum Hypertens 1991;5:115-119.
21. Nazzaro P, Manzari M, Merlo M, Triggiani R, Scarano AM, Lasciarrea A, Pirrelli A. Antihypertensive treatment with verapamil and amlodipine. Their effect on the functional autonomic and cardiovascular stress responses. Eur Heart J 1995;16:1277-1284.
22. de Beider MA, Schneeweiss A, Camm AJ. Evaluation of the efficacy and duration of action of isosorbide mononitrate in angina pectoris. Am J Cardiol 1990;65:6J-8J.
23. Badger RS, Brown BG, Gallery CA, Bolson EL, Dodge HT. Coronary artery dilation and hemodynamic responses after isosorbide dinitrate therapy in patients with coronary artery disease. Am J Cardiol 1985;56:390-395.
24. Abrams J. Interval therapy to avoid nitrate tolerance: Paradise regained? Am J Cardiol 1989;64:931-934.
25. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-1331.
26. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-625.
27. Yusuf S. Calcium antagonists in coronary artery disease and hypertension. Time for reevaluation. Circulation 1995;92: 1079-1082.
28. Opie LH, Messerli FH. Nifedipine and mortality. Grave defects in the dossier. Circulation 1995;92:1068-1073.
29. Kloner RA. Nifedipine in ischemic heart disease. Circulation 1995;92:1074-1078.
30. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and myocardial infarction. A hypothesis formulated but not yet tested. JAMA 1995;274:654-655.
31. Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ, on behalf of the TIBET Study Group. The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. Eur Heart J 1996;17:96-103.
32. Dargie HJ, Ford I, Fox KM, on behalf of the TIBET Study Group. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996;17:104-112.
33. Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol vs. verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996;17:76-81.
34. Packer M, O'Connor CM, Ghali JK, et al. DL, for the prospective randomized amlodipine survival evaluation study group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335: 1107-1114.
35. Rogers WJ, Bourassa MG, Andrews TC, et al. Asymptomatic cardiac ischemia pilot (ACIP) study: Outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization. The ACIP investigators. J Am Coll Cordiol 1995;26:594-605.
36. Quinn TG, Alderman EL, Mcmillan A, Haskell W, for the SCRIP investigators. Development of new coronary atherosclerotic lesions during a 4-year multifactor risk reduction program: The Stanford Coronary Risk Intervention Project (SCRIP). J Am Coll Cordiol 1994;24:900-908.